Compare · ANL vs NVO
ANL vs NVO
Side-by-side comparison of Adlai Nortye Ltd. (ANL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 243.5x ANL ($884.8M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for ANL).
- NVO has more recent analyst coverage (25 ratings vs 7 for ANL).
- Company
- Adlai Nortye Ltd.
- Novo Nordisk A/S
- Price
- $13.65-3.94%
- $48.65+3.65%
- Market cap
- $884.8M
- $215.46B
- 1M return
- +13.94%
- -
- 1Y return
- +737.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 8
- 9
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANL
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by Adlai Nortye Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by Adlai Nortye Ltd.
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
- New insider Birgerson Lars Erik claimed ownership of 166,668 units of American Depositary Shares (SEC Form 3)
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
- SEC Form 424B7 filed by Adlai Nortye Ltd.
- SEC Form 6-K filed by Adlai Nortye Ltd.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S